This press release contains forward looking statements regarding Genzyme's future business plans and strategies, including without limitation, statements regarding ataluren's clinical development, ataluren's potential in indications other than nmDBMD and Genzyme's plans to advance ataluren's development for the treatment of various genetic disorders.